| Subsidiaries and Associates The number of consolidated subsidiaries decreased by 4 in the year ended March 31, 2026, primarily due to liquidations and mergers to reorganize capital in subsidiaries. The number of associates accounted for using the equity method decreased by 5 primarily due to divestitures and liquidations. The following is a listing of the Company’s consolidated subsidiaries (including partnerships): 154 subsidiaries as of March 31, 2026 | | | | | | | | | | | | | | | | | | | Company name | | Country | | Ownership of Voting Rights (%) | | | Takeda Argentina S.A. | | Argentina | | 100.0% | | | Takeda Austria GmbH | | Austria | | 100.0% | | | Takeda Manufacturing Austria AG | | Austria | | 100.0% | | | Baxalta Innovations GmbH | | Austria | | 100.0% | | | Baxalta Belgium Manufacturing S.A. | | Belgium | | 100.0% | | | Takeda Distribuidora Ltda. | | Brazil | | 100.0% | | | Takeda Pharma Ltda. | | Brazil | | 100.0% | | | Takeda Canada Inc. | | Canada | | 100.0% | | | Takeda (China) Holdings Co., Ltd. | | China | | 100.0% | | | Takeda (China) International Trading Co., Ltd. | | China | | 100.0% | | | Tianjin Takeda Pharmaceuticals Co., Ltd. | | China | | 100.0% | | | Takeda APAC Biopharmaceutical Research and Development Co., Ltd. | | China | | 100.0% | | | Takeda France S.A.S. | | France | | 100.0% | | | Takeda GmbH | | Germany | | 100.0% | | | Takeda Ireland Limited | | Ireland | | 100.0% | | | Shire Acquisitions Investments Ireland Designated Activity Company | | Ireland | | 100.0% | | | Shire Ireland Finance Trading Limited | | Ireland | | 100.0% | | | Takeda Italia S.p.A. | | Italy | | 100.0% | | | Takeda Pharmaceuticals Korea Co., Ltd. | | Korea | | 100.0% | | | Takeda Mexico S.A.de C.V. | | Mexico | | 100.0% | | | Takeda Nederland B.V. | | Netherlands | | 100.0% | | | Takeda Pharmaceuticals Limited Liability Company | | Russia | | 100.0% | | | Takeda Manufacturing Singapore Pte. Ltd. | | Singapore | | 100.0% | | | Takeda Farmaceutica Espana S.A. | | Spain | | 100.0% | | | Takeda Pharma AB | | Sweden | | 100.0% | | | Takeda Pharmaceuticals International AG | | Switzerland | | 100.0% | | | Baxalta Manufacturing S.à r.l. | | Switzerland | | 100.0% | | | Takeda Pharma AG | | Switzerland | | 100.0% | | | Takeda UK Limited | | United Kingdom | | 100.0% | | | Takeda Pharmaceuticals U.S.A., Inc. | | U.S. | | 100.0% | | | Takeda Pharmaceuticals America, Inc. | | U.S. | | 100.0% | | | Takeda Vaccines, Inc. | | U.S. | | 100.0% | | | Takeda Development Center Americas, Inc. | | U.S. | | 100.0% | | | Baxalta Incorporated | | U.S. | | 100.0% | | | Dyax Corp. | | U.S. | | 100.0% | | | Takeda Ventures, Inc. | | U.S. | | 100.0% | | | Baxalta US Inc. | | U.S. | | 100.0% | | | Shire Human Genetic Therapies, Inc. | | U.S. | | 100.0% | |
| | | | | | | | | | | | | | | | | | | Company name | | Country | | Ownership of Voting Rights (%) | | | BioLife Plasma Services LP | | U.S. | | 100.0% | | | Takeda Manufacturing U.S.A., Inc. | | U.S. | | 100.0% | | | Takeda U.S. Financing, Inc. | | U.S. | | 100.0% | | Other 113 subsidiaries | | | | | | | | | | | |
|